Literature DB >> 12527699

Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans.

Bjarte Furnes1, Jinong Feng, Steve S Sommer, Daniel Schlenk.   

Abstract

Sequence polymorphisms in enzymes involved in drug metabolism have been widely implicated in the differences observed in the sensitivity to various xenobiotics. The flavin-containing monooxygenase (FMO) gene family in humans catalyzes the monooxygenation of numerous N-, P- and S-containing drugs, pesticides, and environmental toxicants. Six genes (FMO1-6) have been identified so far, but the major alleles of FMO2 and FMO6 encode nonfunctional proteins due to a nonsense mutation and splice-site abnormalities, respectively. Data on structural variants exist for human FMO2 and 3, whereas very little is known about the other FMO genes. FMO1-6 were scanned in 50 individuals of African-American descent using the method, detection of virtually all mutations-single-strand conformational polymorphism. A total of 49 sequence variants were identified in a total 1.35 megabases of scanned sequence, of which 29 were variants affecting protein structure or expression. Some of these are expected to affect the activity of the protein, including a nonsense mutation in FMO1 (R502X) and missense mutations in FMO1 (I303T), FMO4 (E339Q), and FMO5 (P457L) that occur in highly conserved amino acids. Additional deleterious substitutions in FMO2 (del337G) and FMO6 (Q105X) were also identified. Multiple structural variants in the FMO gene family were observed in this African-American sample. Some of the substitutions identified in this study might be useful markers in future association studies assessing sensitivity to environmental toxicants and common disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527699     DOI: 10.1124/dmd.31.2.187

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  19 in total

1.  Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients.

Authors:  Tariq Shafi; Neil R Powe; Timothy W Meyer; Seungyoung Hwang; Xin Hai; Michal L Melamed; Tanushree Banerjee; Josef Coresh; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2016-07-19       Impact factor: 10.121

2.  Mechanism of action of a flavin-containing monooxygenase.

Authors:  Subramaniam Eswaramoorthy; Jeffrey B Bonanno; Stephen K Burley; Subramanyam Swaminathan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-15       Impact factor: 11.205

3.  Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide.

Authors:  Lisbeth K Siddens; Sharon K Krueger; Marilyn C Henderson; David E Williams
Journal:  Biochem Pharmacol       Date:  2014-02-19       Impact factor: 5.858

Review 4.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

5.  Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.

Authors:  Sharon K Krueger; Lisbeth K Siddens; Marilyn C Henderson; Eric A Andreasen; Robert L Tanguay; Clifford B Pereira; Erwin T Cabacungan; Ronald N Hines; Kristin G Ardlie; David E Williams
Journal:  Pharmacogenet Genomics       Date:  2005-04       Impact factor: 2.089

6.  Trimethylaminuria: causes and diagnosis of a socially distressing condition.

Authors:  Richard J Mackay; Christopher J McEntyre; Caroline Henderson; Michael Lever; Peter M George
Journal:  Clin Biochem Rev       Date:  2011-02

7.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

8.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.

Authors:  Sharon K Krueger; Marilyn C Henderson; Lisbeth K Siddens; Jonathan E VanDyke; Abby D Benninghoff; P Andrew Karplus; Bjarte Furnes; Daniel Schlenk; David E Williams
Journal:  Drug Metab Dispos       Date:  2009-05-06       Impact factor: 3.922

9.  The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa.

Authors:  Krishna R Veeramah; Mark G Thomas; Michael E Weale; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Nancy R Mendell; Elizabeth A Shephard; Neil Bradman; Ian R Phillips
Journal:  Pharmacogenet Genomics       Date:  2008-10       Impact factor: 2.089

10.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.